Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 14/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20512902 | 1.00 | GPR119 (0.41) | GPR119TRPA1SLC22A12EGLN2KDM1A | |
| SCHEMBL20512862 | 0.86 | CYP11B2 (0.41) | SLC22A12KDM1ACYP11B1CYP11B2 | |
| SCHEMBL20512647 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20512514 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20512516 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL23496011 | 0.80 | KDM1A (0.48) | GPR119KDM1A | |
| SCHEMBL20512481 | 0.80 | KDM1A (0.48) | GPR119KDM1A | |
| SCHEMBL20512598 | 0.79 | TRPA1 (0.47) | GPR119TRPA1SLC22A12EGLN2KDM1A | |
| SCHEMBL17981584 | 0.79 | BACE1 (0.40) | — | |
| SCHEMBL29927427 | 0.78 | KDM1A (0.48) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | KDM1B, KDM1A, DOT1L | GPR119 577/4885TRPA1 3202/4885SLC22A12 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.